MYRIAD GENETICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.

NEW YORK, April 25, 2018 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased or otherwise acquired securities of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ:MYGN) between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”).

Investors who have incurred losses in shares of Myriad Genetics, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of Myriad Genetics, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Myriad Genetics, Inc.

The filed complaint filed alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that:

• Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for Myriad’s hereditary cancer testing;
   
• the foregoing conduct would foreseeably subject Myriad to heightened regulatory scrutiny and/or enforcement action;
   
• Myriad’s revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable; and
   
• as a result, Myriad’s public statements were materially false and misleading at all relevant times.

On March 12, 2018, Myriad disclosed that it received a subpoena from the Department of Health and Human  Services  (DHHS) in connection with an investigation into possible false Medicare and Medicaid payment claims. The subpoena purportedly requested documents “relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.”

On this news, Myriad’s share price fell $4.01 per share, or 12.1%, to close at $29.01 per share on March 13, 2018.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.